Generate Biomedicines, Inc. Common Stock Net Assets
Generate Biomedicines, Inc. Common Stock net assets. Based on the latest financial reports, Generate Biomedicines, Inc. Common Stock (GENB) has net assets worth $456.05 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($561.69 Million) and total liabilities ($105.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Generate Biomedicines, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $456.05 Million |
| % of Total Assets | 81.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Generate Biomedicines, Inc. Common Stock (2024–2025)
Net assets of Generate Biomedicines, Inc. Common Stock from 2024 to 2025. This chart illustrates how Generate Biomedicines, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See how leveraged is Generate Biomedicines, Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Generate Biomedicines, Inc. Common Stock from 2024 to 2025. For live market cap and overall valuation, see market cap of Generate Biomedicines, Inc. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-623.20 Million | -43.23% |
| 2024-12-31 | $-435.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Generate Biomedicines, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20315400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Generate Biomedicines, Inc. Common Stock Net Assets Breakdown (December 2025)
Generate Biomedicines, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $50.00K | % |
| Other Comprehensive Income | $106.00K | % |
| Other Components | $60.17 Million | % |
| Total Equity | $-615.97 Million | 100.00% |
Generate Biomedicines, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Generate Biomedicines, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gelsenwasser AG
F:WWG
|
$1.86 Billion |
|
Sinda Ltd.
NYSE:SIND
|
$1.86 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
$1.86 Billion |
|
UIE PLC
CO:UIE
|
$1.86 Billion |
|
Veris Residential Inc
NYSE:VRE
|
$1.86 Billion |
|
Blackstone Mortgage Trust Inc
NYSE:BXMT
|
$1.86 Billion |
|
CHN Energy Changyuan Electric Power Co Ltd
SHE:000966
|
$1.85 Billion |
|
Argan SA
PA:ARG
|
$1.85 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Generate Biomedicines, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -434,519,000 to -615,965,000, a change of -181,446,000.
- Net loss of 203,154,000 reduced equity.
- New share issuances of 21,973,000 increased equity.
- Other comprehensive income decreased equity by 12,000.
- Other factors decreased equity by 253,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-203.15 Million | -32.98% |
| Share Issuances | $21.97 Million | +3.57% |
| Other Comprehensive Income | $-12.00K | -0.0% |
| Other Changes | $-253.00K | -0.04% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Generate Biomedicines, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-3.41 | $14.46 | x |
| 2025-12-31 | $-12.30 | $14.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Generate Biomedicines, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -636.99%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | -849.36% | 0.04x | 0.00x | $-130.32 Million |
| 2025 | 0.00% | -636.99% | 0.10x | 0.00x | $-141.56 Million |
Industry Comparison
This section compares Generate Biomedicines, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Generate Biomedicines, Inc. Common Stock (GENB) | $456.05 Million | 0.00% | 0.23x | $1.86 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is … Read more